Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • About Us
    • About JPET
    • Feedback
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • About Us
    • About JPET
    • Feedback
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleDrug Discovery and Translational Medicine

Pharmaceutical characterization of tropomyosin receptor kinase B-agonistic antibodies on human iPS cell-derived neurons

Stefanie Traub, Heiko Stahl, Holger Rosenbrock, Eric Simon, Lore Florin, Lisa Hospach, Stefan Hoerer and Ralf Heilker
Journal of Pharmacology and Experimental Therapeutics March 28, 2017, jpet.117.240184; DOI: https://doi.org/10.1124/jpet.117.240184
Stefanie Traub
Trenzyme GmbH;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heiko Stahl
Boehringer Ingelheim GmbH & Co KG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Holger Rosenbrock
Boehringer Ingelheim GmbH & Co KG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Simon
Boehringer Ingelheim GmbH & Co KG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lore Florin
Boehringer Ingelheim GmbH & Co KG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa Hospach
Boehringer Ingelheim GmbH & Co KG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Hoerer
Boehringer Ingelheim GmbH & Co KG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralf Heilker
Boehringer Ingelheim GmbH & Co KG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Brain-derived neurotrophic factor (BDNF) is a central modulator of neuronal development and synaptic plasticity in the central nervous system (CNS). This renders the BDNF-modulated tropomyosin receptor kinase B (TrkB) a promising drug target to treat synaptic dysfunctions. Using GRowth factor-driven expansion and INhibition of NotCH during maturation, the so-called GRINCH neurons were derived from human induced pluripotent stem (hiPS) cells. These GRINCH neurons were employed as model cells for pharmacological profiling of two TrkB-agonistic antibodies, hereafter referred to as AB2 and AB20. In next generation sequencing (NGS) studies, AB2 and AB20 stimulated transcriptional changes, which extensively overlapped with BDNF-driven transcriptional modulation. In regard to TrkB phosphorylation, both AB2 and AB20 were only about half as efficacious as BDNF. However, with respect to the TrkB downstream signaling, AB2 and AB20 displayed increased efficacy values, providing a stimulation at least comparable to BDNF in respect of VGF transcription as well as of AKT and CREB phosphorylation. In a complex structure of the TrkB-d5 domain with AB20, determined by x-ray crystallography, the AB20 binding site was found to be allosteric in regard to the BDNF binding site while AB2 was known to act orthosterically with BDNF. In agreement with this finding, AB2 and AB20 acted synergistically at higher concentrations to drive TrkB phosphorylation. Whilst TrkB downstream signaling declined faster after pulse stimulation with AB20 than with AB2, AB20 restimulated TrkB phosphorylation more efficiently than AB2. In conclusion, both antibodies displayed some limitations and some benefits in regard to future applications as therapeutic agents. 

  • antibodies
  • BDNF
  • drug discovery
  • drug efficacy
  • neurotrophic factors
  • The American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 365 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 365, Issue 2
1 May 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmaceutical characterization of tropomyosin receptor kinase B-agonistic antibodies on human iPS cell-derived neurons
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
Citation Tools
Research ArticleDrug Discovery and Translational Medicine

Pharmaceutical characterization of tropomyosin receptor kinase B-agonistic antibodies on human iPS cell-derived neurons

Stefanie Traub, Heiko Stahl, Holger Rosenbrock, Eric Simon, Lore Florin, Lisa Hospach, Stefan Hoerer and Ralf Heilker
Journal of Pharmacology and Experimental Therapeutics March 28, 2017, jpet.117.240184; DOI: https://doi.org/10.1124/jpet.117.240184

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleDrug Discovery and Translational Medicine

Pharmaceutical characterization of tropomyosin receptor kinase B-agonistic antibodies on human iPS cell-derived neurons

Stefanie Traub, Heiko Stahl, Holger Rosenbrock, Eric Simon, Lore Florin, Lisa Hospach, Stefan Hoerer and Ralf Heilker
Journal of Pharmacology and Experimental Therapeutics March 28, 2017, jpet.117.240184; DOI: https://doi.org/10.1124/jpet.117.240184
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • ONO-8590580, a novel GABAA α5 negative allosteric modulator enhances long-term potentiation and improves cognitive deficits in preclinical models.
  • Intravenous and intratracheal thyrotropin releasing hormone and its analog taltirelin reverse opioid-induced respiratory depression in isoflurane anesthetized rats
  • DLX1008, Angiogenesis, and Glioblastoma
Show more Drug Discovery and Translational Medicine

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2018 by the American Society for Pharmacology and Experimental Therapeutics